Recombinant human erythropoietin treatment of postpartum anemiaPreliminary results

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 81, Issue 1, 1998, Pages 27-31

  Makrydimas, George ^a   Lolis, Dimitrios ^a   Lialios, Georgios ^a   Tsiara, Stavroula ^a   Georgiou, Ioannis ^a   Bourantas, Konstantinos L ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Postpartum anemia; Recombinant human erythropoietin; Transfusions

Indexed keywords

ANTIANEMIC AGENT; FOLIC ACID; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PUERPERAL DISORDER; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032190495     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00158-4     Document Type: Article

References (14)

1. [1] Gilbert I, Porter W, Brown VA. Postpartum haemorrhage - a continuing problem. Br J Obstet Gynaecol 1987;94:67-71.
2. [2] Huch A, Eichhorn KH, Danko J, Lauener PA, Huch R. Recombinant human erythropoietin in the treatment of postpartum anemia. Obstet Gynecol 1992;80:127-31.
3. [3] Zimmerman R, Breymann C, Richter C, Huch R, Huch A. rHuEpo treatment of postpartum anemia. J Perinat Med 1995;23:111-7.
4. [4] American College of Obstetricians and Gynecologists. Ratschlage fur die praxis in geburtshife und gynakologie. Diagnose und behandlung postpartaler blutunger. German edition, ACOG technical bulletin no. 143. In: Geburtshilfe Frauenheilkd 1990;51:53-7.
5. [5] Nolan TE, Gallup DG. Massive transfusion: a current review. Obstet Gynecol Surv 1991;46:289-95.
6. [6] Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. New Engl J Med 1987;316:73-8.
7. [7] Bourantas KL, Tsiara St, Christou L, et al. Combination therapy with recombinant human erythropoietin, interferon-α-2b and granulocyte macrophage colony-stimulating factor in idiopathic myelofibrosis. Acta Haematol 1996;96:79-82.
8. [8] Bourantas KL, Makrydimas G, Georgiou J, Tsiara St, Lolis D. Preliminary results with administration of recombinant human erythropoietin in sickle cell/β-thalassemia patients during pregnancy [letter]. Eur J Haematol 1995;56:326-8.
9. [9] Bourantas KL, Economou G, Georgiou J. Administration of high doses of recombinant human erythropoietin to patients with β-thalassemia intermedia: a preliminary trial. Eur J Haematol 1997;58:22-5.
10. [10] Davis HP. Erythropoietin for patients refusing blood transfusion. Lancet 1990;336:384-5.
11. [11] Gabrilove JL. Introduction and overview of hematopoietic growth factors. Semin Hematol 1989;26(Suppl 2): 1-4.
12. [12] Kurtz A, Eckardt KU, Tannahill L, Bauer C. Regulation of erythropoietin production. Contrib Nephrol 1988;66:1-16.
13. [13] Eckardt KU. The autogeny of the biological role and production of erythropoietin. J Perinat Med 1995;23:19-29.
14. [14] Van Wyck DB. Iron management during recombinant human erythropoietin therapy. Am J Kidney Dis 1989;14(Suppl 1):9-13.